<DOC>
	<DOCNO>NCT00398931</DOCNO>
	<brief_summary>This study conduct among woman previously receive alendronate 3 6 year Fracture Intervention Trial ( FIT ) . Participants FLEX study randomly assign receive alendronate ( either 5 10 mg/day ) match placebo next 5 year , order evaluate effect continue discontinue alendronate treatment bone mineral density biochemical marker bone turnover .</brief_summary>
	<brief_title>FLEX - Long-term Extension FIT ( Fracture Intervention Trial ) ( 0217-051 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>To eligible participate study , woman need previously participate Fracture Intervention Trial ( FIT ) part group treat alendronate FIT They need receive least 3 year treatment alendronate FIT trial In addition , bone mineral density ( BMD ) hip need well start FIT Patients exclude condition contraindicate alendronate therapy might use medication treatment osteoporosis Women also exclude BMD hip certain level ( Tscore &lt; =3.5 ) ; , 3.5 standard deviation low average young adult woman</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>